AstraZeneca cancer drug secures US approval
By Abigail Townsend
Date: Thursday 05 Dec 2024
(Sharecast News) - AstraZeneca drug Imfinzi has been approved for use in the US for patients with limited stage small cell lung cancer, the biopharmaceutical specialist confirmed on Thursday.
LS-SCLC is a highly aggressive form of cancer. Currently only 15% to 30% of patients with LS-SCLC are alive five years after diagnosis.
The US Food and Drug Administration approved Imfinzi for use on adult patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Approval was based on Adriatic phase III trial results that showed a 27% reduction in the risk of death versus the placebo, AstraZeneca said.
Dave Fredrickson, executive vice president at AstraZeneca's oncology business unit, said it was a "breakthrough" for LS-SCLC patients.
He continued: "Imfinzi is now the only immunotherapy approved for both limited and extensive stage small cell lunch cancer, underscoring our commitment to improving survival rates."
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN